NSAID enteropathy and bacteria: a complicated relationship

Area of Science:

• Gastroenterology
• Microbiology
• Pharmacology

Background:

• Small intestinal damage from nonsteroidal anti-inflammatory drugs (NSAIDs) is frequent but underdiagnosed.
• NSAID enteropathy pathogenesis involves bacteria, bile, and enterohepatic circulation, with Gram-negative bacteria playing a key role.
• Gastric acid secretion inhibitors worsen NSAID enteropathy by altering the intestinal microbiome.

Purpose of the Study:

• To elucidate the pathogenesis of NSAID enteropathy.
• To investigate the role of the intestinal microbiome in NSAID enteropathy.
• To evaluate the therapeutic potential of probiotics in preventing NSAID-induced intestinal damage.

Main Methods:

• Analysis of factors contributing to NSAID enteropathy, including bacterial and bile interactions.
• Investigation of the impact of gastric acid inhibitors on the intestinal microbiome.
• Assessment of antibiotic and probiotic interventions in animal models of NSAID enteropathy.

Main Results:

• NSAID enteropathy is multifactorial, with bacterial enzymes, bile, and enterohepatic circulation being crucial.
• Gram-negative bacteria and endotoxin may contribute to NSAID enteropathy pathogenesis.
• Probiotics, specifically Bifidobacterium, Lactobacillus, and Faecalibacteriaum prausnitzii, showed promise in animal models, likely via colonization.

Conclusions:

• NSAID enteropathy is a significant clinical issue requiring further understanding.
• The intestinal microbiome is a critical factor in NSAID enteropathy development and potential treatment.
• Probiotic colonization, rather than secreted products, appears to be the mechanism for therapeutic benefit in NSAID enteropathy.